ArticleBlood neoplasia2026
Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.
Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03598608 (A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The MK-4280-003 study evaluated favezelimab plus pembrolizumab in hematologic malignancies. We report results for anti-programmed cell death protein 1 (PD-1)-refractory classic Hodgkin lymphoma (cHL; cohort 2). Participants in the safety lead-in had relapsed or refractory (R/R) cHL, diffuse large B-cell lymphoma, or indolent B-cell lymphoma. Participants in cohort 2 had R/R cHL, had undergone or were ineligible for autologous stem cell transplantation, and had disease progression after ≥2 doses of anti-PD-1 therapy and within 12 weeks of last dose. Primary end points were safety and the recommended phase 2 dose (RP2D) of favezelimab plus pembrolizumab. Objective response rate (ORR) was secondary. Duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were exploratory. In the safety lead-in, 1 of 21 participants experienced a dose-limiting toxicity (grade 4 autoimmune hepatitis). The RP2D was favezelimab 800 mg plus pembrolizumab 200 mg IV every 3 weeks. Cohort 2 included 34 participants. Treatment-related adverse events (AEs) occurred in 28 participants (82%; grade 3 or 4 in 6 participants [18%]; no grade 5 AEs). Immune-mediated AEs and infusion reactions occurred in 17 participants (50%; grade 3 or 4 in 3 participants [9%]; no grade 5 AEs). ORR was 29% (95% confidence interval [CI], 15-48). Median DOR was 21.9 months (range, 0.0+ to 26.1+). Median PFS was 9.7 months (95% CI, 5.1-14.7); 24-month PFS was 21%. Median OS was not reached (NR; 95% CI, 27.9 to NR); 24-month OS was 76%. Favezelimab plus pembrolizumab showed manageable safety and antitumor activity in heavily pretreated anti-PD-1-refractory cHL. This trial was registered at www.clinicaltrials.gov as NCT03598608.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.